The following publications are related to the DIMSCAN system :


Papers on DIMSCAN development

Authors

Paper name

Published in

Year

Proffitt RT, Tran JV, Reynolds CP

A fluorescence digital image microscopy system for quantitating relative cell numbers in tissue culture plates

Cytometry 24:204-213

1996

Krejsa J, Frgala F, Alfaro P, Reynolds CP

DIMSCAN 3.0, A New Generation of Fluorescence Digital Image Microscopy System for Measuring Cytotoxicity in Microplates

2002 AACR Annual Meeting (poster)

2002

Ondrej Kalous, Julie Watanabe, Kun Jung Lee, A. Linn Murphree, C. Patrick Reynolds

Use Of A Novel Microplate Fluorescence Cytotoxicity Assay (Dimscan-384) To Evaluate Combinations Of Cytotoxic Agents In A Panel Of Retinoblastoma Cell Lines

2003 AACR Annual Meeting

2003

Ondrej Kalous, Jiri Krejsa, Tomas Frgala, C. Patrick Reynolds

The DIMSCAN cytotoxicity assay, unlike the MTT assay, identifies syngergistic combinations of anticancer agents.

2004 AACR Annual Meeting

2004

Keshelava, N., Frgala, T., Krejsa, J., Kalous, O., and Reynolds, C. P.

DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.

Methods Mol.Med., 110: 139-153

2005

Frgala T, Kalous O, Proffitt RT, Reynolds CP

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.

Mol Cancer Ther, 6(3):886-97

2007


[ Back to Top ]

Papers using DIMSCAN:

Authors

Paper name

Published in

Year

Reynolds CP, Schindler P, Jones D, Gentile J, Proffitt R, Einhorn P

Comparison of 13-cis- retinoic acid to trans-retinoic acid using human neuroblastoma cell lines

Advances in Neuroblastoma Research 4, Evans A, Biedler JL, Brodeur G, D'Angio GJ, Nakagawara A (eds.), New York: John Wiley & Sons, 237-244

1994

Keshelava N, Seeger RC, Reynolds CP

Drug resistance phenotype of neuroblastoma cell lines established at diagnosis and at relapse after induction chemotherapy or bone marrow transplantation

European J Cancer33:2002-2006

1997

Anderson CP, Tsai JM, Chan WW, Liu RM, Forman HJ, Reynolds CP

Buthionine sulfoximine (BSO) is cytotoxic via apoptosis and synergistically enhances the activity of melphalan (L-PAM) in human neuroblastoma cell lines

European J Cancer 33:2016-2019

1997

Keshelava N, Seeger RC, Groshen S, Reynolds CP

Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy

Cancer Research 58:5396-5405

1998

Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds G P

Depletion of Glutathione (GSH) by buthionine sulfoximine (BSO) is cytotoxic for human neuroblastoma cell lines via apoptosis

Experimental Cell Research 246:183-192

1999

Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP

N-(4-hydroxypheynl)retinamide increases ceramide and reactive oxygen species and induces mixed apoptosis/necrosis in neuroblastoma cell lines

J Natl Cancer Inst 91:1138-1146

1999

Keshelava N, Groshen S, Reynolds CP

Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines

Cancer Chemotherapy and Pharmacology 45:1-8

2000

Chen RL, Reynolds CP, Seeger RC, Cabot MC, Reynolds CP

Neutrophils are cytotoxic and growth inhibiting for neuroblastoma cells with anti-GD2 antibody but without cytotoxicity can be growth stimulating

Clinical Immunol Immunother 48:603-612

2000

Maurer BJ, Cabot MC, Reynolds CP

Synergism of  N-(4-hydroxyphenyl)retinamide cytotoxicity by modulators of ceramide metabolism in solid tumor cell lines

J Natl Cancer Inst 92:1897-1908

2000

Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ

Retinoic-acid resistant neuroblastoma cell lines show altered myc regulation and high sensitivity to fenretinide

Medical Pediatric Oncology 35:597-602

2000

Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche CJ, Reynolds CP

Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines

Cancer Research 61:6185-6193

2001

Anderson CP, Seeger RC, Satake N, Meek WE, Keshelava N, Bailey HH, Monforte-Munoz HL, Reynolds CP

Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line

J Pediat Hematol Oncol  23:500-505

2001

Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC

Enhanced expression and activation of Mac-1 (CD11b/CD18) by an anti-GD2/GM-CSF fusion protein increases neutrophil antibody dependent cellular cytotoxicity

Blood 99:4166-4173

2002

O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ

N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes

Leukemia 16:902-910

2002

Anderson C, Reynolds CP

Cytotoxicity of buthionine sulfoximine (BSO) and melphalan/BSO in combination for neuroblastoma cell lines derived after myeloablative therapy

Bone Marrow Transplantation 30:135-140

2002

Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, and Malcolm A. Smith

Testing of New Agents in Childhood Cancer Preclinical Models : Meeting Summary

Clinical Cancer Research 8:3646-3657

2002

Bo Yang, Nino Keshelava, Clarke P. Anderson, and C. Patrick Reynolds

Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine

Cancer Research 63:1520-1526

2003

Nino Keshelava, Denice Tsao-Wei, and C. Patrick Reynolds

Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p531

Clinical Cancer Research 9:3492-3502

2003

Grigoryan, R., Keshelava, N., Anderson, C., and Reynolds, C. P.

In vitro testing of chemosensitivity in physiological hypoxia.

Methods Mol.Med., 110: 87-100

2005

Reynolds, C. P. and Maurer, B. J.

Evaluating response to antineoplastic drug combinations in tissue culture models.

Methods Mol.Med., 110: 173-183

2005

Yang, B. and Reynolds, C. P.

Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.

Clin.Cancer Res., 11: 2774-2780

2005

Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Tony Ng T, Reynolds CP, Triche TJ, Sorensen PHB

E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.

Cancer Research, 67: 3094-3105

2007

Houghton PJ, Morton CL, Tucker C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Wu J, Smith MA

Stage 1 testing of the proteasome inhibitor bortezomib by the Pediatric Preclinical Testing Program.

Pediatric Blood & Cancer, (In Press).

2007

Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP

Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents.

J National Cancer Institute, 99:1107-19

2007

Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA

Initial testing (Stage 1) of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program.

Pediatric Blood & Cancer., (In Press)

2007

Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Lock RB, Reynolds CP

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

Blood, 110:205-2066

2007

Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB

Initial testing (Stage 1) of cisplatin by the Pediatric Preclinical Testing Program.

Pediatric Blood & Cancer, (In Press)

2007

Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA

Initial testing of dasatinib by the Pediatric Preclinical Testing Program.

Pediatric Blood & Cancer, (In Press)

2007

Reynolds CP, Kang MH, Keshelava N, Mauer BJ

Assessing combinations of cytotoxic agents using leukemia cell lines.

Current Drug Targets, 8:765-771

2007


[ Back to Top ]

Clinical Trials Enabled by DIMSCAN Testing:

Authors

Paper name

Published in

Year

Villablanca JG, Avramis V, Khan A, Matthay KK, Ram say NKC, Seeger RC, Reynolds CP

Phase I trial of 13-cis-retinoic acid (cRA) in neuroblastoma patients following bone marrow transplantation (BMT)

J Clinical Oncology 13:894-901

1995

Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shamada H, Black CG, Brodeur GM, Gerbing R, Reynolds CP

Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid

New Eng J Med 341:1165-1173

1999

Villablanca JG, Ames MM, Reid JM, Bagniewski P, Krail M, Reynolds CP

Phase I trial of oral [N- (-4-hydroxyphenyl) retinamide] (4-HPR) in children with resistant/recurrent solid tumors: A Children's Cancer Group Study (CCG 09709)

Proc Amer Soc Clin Oncol 21:398a

J Clinical Oncology 24:3423-3430

2002


2006

Anderson CP, Robert Seeger RC, Bailey H, Reynolds CP

Pilot of buthionine sulfoximine (BSO) combined with non-myeloablative melphalan (L-PAM) against refractory neuroblastoma (NB)

Proc Amer Soc Clin Oncol 21 :298a

2002

New Approaches to Neuroblastoma Therapy

N2002-01: A Phase I Study of High-Dose Pyrazoloacridine (PZA) (NSC 366140) Supported with Autologous Hematopoietic Stem Cell Rescue in Children with Recurrent or Resistant Neuroblastoma.

Closed

 

Children's Oncology Group

ANBL0321: A Phase II Study of Fenretinide in Children with Recurrent/Resistant High Risk Neuroblastoma.

Ongoing

 

New Approaches to Neuroblastoma Therapy

N99-02: A Phase I trial of BSO + L-PAM and Stem Cell Support.

Ongoing

 

Norris Cancer Center

A Phase II trial of Fenretinide in Recurrent Ovarian Cancer.

Proc Amer Soc Clin Oncol 23:461

Proc Amer Soc Clin Oncol 25: Abst 5555

2004


2007

California Cancer Consortium

A Phase II trial of Fenretinide in Prostate Cancer.

Ongoing

 

California Cancer Consortium

A Phase I trial of Intravenous Fenretinide in Hematological Malignancies.

Ongoing

 

California Cancer Consortium

A phase I trial of intravenous fenretinide in solid tumors

Ongoing

 

California Cancer Consortium

A phase II trial of fenretinide in asymptomatic rising PSA prostate cancer

Completed

 

New Approaches to Neuroblastoma Therapy

N2004-04: A Phase I Study of Fenretinide Lym-X-SorbTM (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (IND # 68,254)

Ongoing

 

Therapeutic Advances in Childhood Leukemia

TACL 2005-001: A phase I/II trial of ABT-751 combined with dexamethasone, PEG-asparaginase, and doxorubicin in relapsed acute lymphoblastic leukemia (ALL)

Ongoing

 

Therapeutic Advances in Childhood Leukemia

TACL 2005-003: Bortezomib with chemotherapy for relapsed childhood ALL.

Ongoing

 

Therapeutic Advances in Childhood Leukemia

TACL 2006-001: IV Fenretinide in Relapsed ALL, AML or NHL.

Ongoing

 

[ Back to Top ]

© BioImaging Solutions, Inc. (2009-2014)